Eton Pharmaceuticals (NASDAQ:ETON) reported fourth quarter 2025 product revenue of $21.3 million, an 83% increase from $11.6 million in the prior-year period, as the company highlighted continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results